The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
(1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks. (2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treate...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/10/11/261 |
id |
doaj-b14e64cf97994482ac5b295ec0cc808a |
---|---|
record_format |
Article |
spelling |
doaj-b14e64cf97994482ac5b295ec0cc808a2020-11-25T04:04:22ZengMDPI AGLife2075-17292020-10-011026126110.3390/life10110261The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical CareAsuka Inoue0Yuji Nozaki1Yasuaki Hirooka2Koji Kinoshita3Yasutaka Chiba4Masanori Funauchi5Itaru Matsumura6Department of Rheumatology, Kindai University Nara Hospital, Nara 630-0293, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Rheumatology, Kindai University Nara Hospital, Nara 630-0293, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Clinical Research Center, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, Japan(1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks. (2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treated with MTX+IGU (<i>n</i> = 35) and those treated with IGU (<i>n</i> = 71). The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Secondary endpoints, such as the clinical response, retention rate, and safety, were evaluated. (3) Results: The DAS28-CRP difference in the changes between the two groups were −0.2. DAS28-CRP were significantly reduced from the baseline in the MTX+IGU and IGU groups (−1.43 and −1.20 from baseline, respectively). The retention rates were 71.4% in the MTX+IGU groups and 59.2% in the IGU groups (<i>p</i> = 0.16). Adverse events were observed in a total of 6 (17.1%) MTX+IGU patients and 20 (28.2%) IGU patients (<i>p</i> = 0.21). (4) Conclusions: IGU therapy may be a useful treatment option for patients who cannot be treated with MTX.https://www.mdpi.com/2075-1729/10/11/261iguratimodmethotrexaterheumatoid arthritisclinical responseretention rate |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Asuka Inoue Yuji Nozaki Yasuaki Hirooka Koji Kinoshita Yasutaka Chiba Masanori Funauchi Itaru Matsumura |
spellingShingle |
Asuka Inoue Yuji Nozaki Yasuaki Hirooka Koji Kinoshita Yasutaka Chiba Masanori Funauchi Itaru Matsumura The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care Life iguratimod methotrexate rheumatoid arthritis clinical response retention rate |
author_facet |
Asuka Inoue Yuji Nozaki Yasuaki Hirooka Koji Kinoshita Yasutaka Chiba Masanori Funauchi Itaru Matsumura |
author_sort |
Asuka Inoue |
title |
The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care |
title_short |
The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care |
title_full |
The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care |
title_fullStr |
The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care |
title_full_unstemmed |
The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care |
title_sort |
effectiveness and retention rate of iguratimod in japanese rheumatoid arthritis patients with/without methotrexate in daily medical care |
publisher |
MDPI AG |
series |
Life |
issn |
2075-1729 |
publishDate |
2020-10-01 |
description |
(1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks. (2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treated with MTX+IGU (<i>n</i> = 35) and those treated with IGU (<i>n</i> = 71). The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Secondary endpoints, such as the clinical response, retention rate, and safety, were evaluated. (3) Results: The DAS28-CRP difference in the changes between the two groups were −0.2. DAS28-CRP were significantly reduced from the baseline in the MTX+IGU and IGU groups (−1.43 and −1.20 from baseline, respectively). The retention rates were 71.4% in the MTX+IGU groups and 59.2% in the IGU groups (<i>p</i> = 0.16). Adverse events were observed in a total of 6 (17.1%) MTX+IGU patients and 20 (28.2%) IGU patients (<i>p</i> = 0.21). (4) Conclusions: IGU therapy may be a useful treatment option for patients who cannot be treated with MTX. |
topic |
iguratimod methotrexate rheumatoid arthritis clinical response retention rate |
url |
https://www.mdpi.com/2075-1729/10/11/261 |
work_keys_str_mv |
AT asukainoue theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT yujinozaki theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT yasuakihirooka theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT kojikinoshita theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT yasutakachiba theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT masanorifunauchi theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT itarumatsumura theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT asukainoue effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT yujinozaki effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT yasuakihirooka effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT kojikinoshita effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT yasutakachiba effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT masanorifunauchi effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare AT itarumatsumura effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare |
_version_ |
1724437058890498048 |